======= KMT2E =======
== Gene Information ==
* **Official Symbol**: KMT2E
* **Official Name**: lysine methyltransferase 2E
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=55904|55904]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q8IZD2|Q8IZD2]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=KMT2E&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20KMT2E|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/608444|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene is a member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family and encodes a protein with an N-terminal PHD zinc finger and a central SET domain. Overexpression of the protein inhibits cell cycle progression. Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008].
* **UniProt Summary**: N/A
|SET|
|PHD|
|positive regulation of histone H3-K4 trimethylation|
|regulation of histone H3-K4 trimethylation|
|positive regulation of histone H3-K4 methylation|
|histone-lysine N-methyltransferase activity|
|transcriptionally active chromatin|
|regulation of histone H3-K4 methylation|
|positive regulation of G1/S transition of mitotic cell cycle|
|positive regulation of histone methylation|
|positive regulation of cell cycle G1/S phase transition|
|DNA alkylation|
|DNA methylation|
|regulation of megakaryocyte differentiation|
|methylated histone binding|
|regulation of histone methylation|
|DNA methylation or demethylation|
|histone lysine methylation|
|positive regulation of mitotic cell cycle phase transition|
|erythrocyte differentiation|
|peptidyl-lysine methylation|
|DNA modification|
|erythrocyte homeostasis|
|positive regulation of histone modification|
|histone methylation|
|positive regulation of cell cycle phase transition|
|positive regulation of chromatin organization|
|myeloid cell homeostasis|
|chromatin|
|protein methylation|
|protein alkylation|
|regulation of histone modification|
|cell cycle arrest|
|regulation of G1/S transition of mitotic cell cycle|
|positive regulation of mitotic cell cycle|
|microtubule organizing center|
|regulation of cell cycle G1/S phase transition|
|positive regulation of chromosome organization|
|regulation of chromatin organization|
|homeostasis of number of cells|
|myeloid cell differentiation|
|regulation of myeloid cell differentiation|
|macromolecule methylation|
|positive regulation of cell cycle process|
|methylation|
|peptidyl-lysine modification|
|enzyme binding|
|regulation of chromosome organization|
|histone modification|
|covalent chromatin modification|
|positive regulation of cell cycle|
|nuclear speck|
|regulation of mitotic cell cycle phase transition|
|regulation of cell cycle phase transition|
|regulation of hemopoiesis|
|neutrophil mediated immunity|
|neutrophil activation|
|granulocyte activation|
|myeloid leukocyte mediated immunity|
|hemopoiesis|
|negative regulation of cell cycle|
|myeloid leukocyte activation|
|protein-containing complex|
|hematopoietic or lymphoid organ development|
|positive regulation of organelle organization|
|regulation of mitotic cell cycle|
|immune system development|
|chromatin organization|
|DNA metabolic process|
|regulation of cell cycle process|
|leukocyte mediated immunity|
|peptidyl-amino acid modification|
|leukocyte activation|
|cell cycle process|
|chromosome organization|
|cell activation|
|immune effector process|
|regulation of cell cycle|
|positive regulation of cellular component organization|
|positive regulation of protein modification process|
|regulation of organelle organization|
|cell cycle|
|positive regulation of transcription, DNA-templated|
|positive regulation of cellular protein metabolic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|homeostatic process|
|regulation of immune system process|
|positive regulation of protein metabolic process|
|positive regulation of RNA metabolic process|
|regulation of cell differentiation|
|regulation of protein modification process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-2.88|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.48|
|[[:results:exp539|42°C R08 exp539]]|-2.3|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-1.96|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-1.94|
|[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|-1.87|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-1.73|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|-1.71|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|-1.71|
|[[:results:exp256|HMS-I1 10μM R06 exp256]]|-1.7|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|1.75|
|[[:results:exp461|BS-181 20μM R08 exp461]]|1.75|
|[[:results:exp145|PNU96415E 10μM R03 exp145]]|1.76|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|1.8|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|1.83|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|1.91|
|[[:results:exp71|KU-0063794 3.8μM R02 exp71]]|1.94|
|[[:results:exp349|Cytochalasin-B 5μM R07 exp349]]|2.09|
|[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|2.13|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|3.59|
^Gene^Correlation^
|[[:human genes:a:ankrd11|ANKRD11]]|0.495|
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 7982
* **Expression level (log2 read counts)**: 7.51
{{:chemogenomics:nalm6 dist.png?nolink |}}